Sep 2018 Neuronascent Awarded $2.25 Million NIH Grant to Develop a Regenerative Therapeutic for Alzheimer’s Disease READ MORE
Nov 2017 Neuronascent Granted Composition of
Matter Patent in Europe for Oral Neuron Regenerative Technology READ MORE
Oct 2017 Opened Fundable Project READ MORE
Apr 2017 Neuronascent Appoints New Board Member. READ MORE
Jan 2017 Neuronascent Announces Third US Patent Issued Covering Therapeutics for Neurodegenerative and Neuropsychiatric Disorders. READ MORE
Apr 2015 Neuronascent Secures Financing for Development of Its Alzheimer's Therapeutic. READ MORE
Feb 2015 Neuronascent Announces Expanded Patent Coverage In US and Russia For Its Alzheimer's Disease and Down Syndrome Therapeutics. READ MORE
Apr 2014 Neuronascent Successfully Completes Pre-IND Meeting with FDA for Alzheimer’s Disease Therapeutic. READ MORE
Jan 2014 Neuronascent, Inc. Announces Issuance of US Patent Covering Second-Generation Neurorestorative Therapeutic Candidate. READ MORE
Nov 2013 Neuronascent, Inc. Alzheimer’s Disease Therapeutic Candidate
Selected for Preclinical Safety Testing. READ MORE
Oct 2011 Neuronascent Issued US Patent for Neurogenesis, Therapeutic Candidates. READ MORE
May 2011 Neuronascent Receives State and Federal Funding for Its Neurogenesis Therapeutic Programs. READ MORE
Sep 2009 Neuronascent to present at Life Sciences Summit 2009. READ MORE
Aug 2008 Neuronascent, Inc. Receives Multiple Fundings for Its Neurogenesis Therapeautic Programs. READ MORE
Jan 2008 State of Maryland Department of Business and Economic Development Challenge Fund Grant awarded. READ MORE
Nov 2007 TEDCO Announces Phase II Maryland Technology Transfer Fund Award with Johnson & Johnson Corporate Office of Science and Technology. READ MORE
Mar 2007 Montgomery County (Maryland) Department of Business and Economic Development grant awarded
Mar 2007 Lifeline Cell Technology, LLC license agreement signed. READ MORE
Apr 2007 Phase II Maryland Technology Transfer Fund/J & J Grant awarded
Jan 2007 Washington Business Journal. View Article
Jul 2006 MIT Technology Review. View Article
Feb 2016 Neuronascent's Research Tool Aimed at Stroke Tolerance is Characterized in 2016 Publication. The title of the article is “Arctic ground squirrel neuronal progenitor cells resist oxygen and glucose deprivation-induced death,” authored by the Founder and colleagues. READ MORE
Sep 2014 NI Research’s September 2014 Issue of NeuroPerspective fully reviews Alzheimer’s therapeutics and prominently mentions Neuronascent, Inc. In covering the different approaches to Alzheimer’s therapeutic development, the review notes that “The one neurogenesis-focused company prioritizing Alzheimer’s is Neuronascent”. NeuroPerspective publisher Dr. Harry Tracy also called Neuronascent “the neurogenesis specialist,” and he selected Neuronascent’s program as one of the ‘Top Ten’ CNS partnering opportunities to be presented at the Informa Therapeutic Area Partnerships conference, which will be held in Boston this November.
Sep 2012 NeuroNascent Aims to Reverse Neurodegenerative Damage. Full BioWorld Today article available
Aug 2009 American Chemical Society,
Presentation - Washington DC
Jun 2009 Power of Ten Conference,
Presentation – Baltimore, MD
Feb 2009 Wharton Health Care Conference,
Presentation – Feb 09, Philadelphia, PA
Dec 2008 MidAtlantic Capital (MAC) Conference,
Presentation – Philadelphia, PA
Oct 2008 MidAtlantic BIO Conference, Presentation – Chantilly, VA
Oct 2008 Charlottesville Venture Business Forum, Presentation — Charlottesville, VA
View Video (Please contact us to obtain a username and password to view this video.)
June 2008 International Society for Neurogenesis Conference, Presentation — Bejing, China
Nov 2007 Society for Neuroscience Conference,
Presentation — San Diego, California
Feb 2007 International Stroke Conference,
Presentation — San Francisco, California.
View Poster | View Text Version
Feb 2006 Current Alzheimer Research,
Publication — Volume 3 Number 1, 55-62
Discovery of Neurogenic, Alzheimer's Disease Therapeutics
News & Events
Mar 2014 Neuronascent to participate in the Redefining Early Stage Investment (RESI) Innovation Challenge, an investment meeting in Boston, MA, March 24, 2014.
May 2012 Dr. Kelleher-Andersson, the President and CSO of Neuronascent, Inc. presented at the annual Neurotechnology Industry Organization meeting in Boston. Kelleher-Andersson led off the Frontiers in Neurotech panel, by describing the large unmet need for disease modifying therapies to treat Alzheimer’s disease, post-traumatic stress disorder and Down syndrome, then suggested how Neuronascent’s first-in-class therapeutic candidates might address those unmet needs.
Mar 2012 Patent claims were issued in South Korea for Neuronascent’s National patent application entitled “Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration”. Patent claims had previously been issued in the US and Russia back in 2011.
Feb 2012 The founder and President of Neuronascent, Inc., Dr. Judith Kelleher-Andersson presented details of Neuronascent’s Alzheimer’s disease and Down syndrome pre-clinical therapeutic candidates at the 14th American Society for Experimental Neurotherapeutics conference in Washington, DC.
Jun 2011 Dr. Kelleher-Andersson, the President and CSO of Neuronascent, is planning to attend the BIO meeting in Washington D.C. This BIO International meeting “is the largest global event for the biotechnology industry”. It also “offers key networking and partnering opportunities” for small biotech companies like Neuronascent.
Dec 2010 Judith Kelleher-Andersson, Ph.D., the founder and CSO of Neuronascent was an invited speaker at CBI’s 4th Annual Alzheimer’s Disease Drug Discovery Summit on December 14th in Washington DC. Dr. Kelleher-Andersson presented work on Neuronascent’s preclinical lead AD candidate and the status of neurogenesis for neurodegenerative diseases in a talk entitled “Utilizing neurogenic therapeutics in an effort to reverse Alzheimer’s disease”.
Dec 2010 Neuronascent receives a Maryland Biotechnology Center Translational Research award for their application entitled “Preclinical Development of Novel Neurogenic Depression Candidate,” The grant of $199,204.88 will support studies to move Neuronascent’s lead depression candidate toward human testing and determine whether this neurogenic agent will also be effective in improving cognitive capacity in young Down syndrome individuals. The Brain Translational Center at Johns Hopkins University under the leadership of Dr. Barbara Slusher will collaborate specifically to scale-up the synthesis of this small molecule compound and to determine if there could be any potential toxicity issues in moving toward human clinical testing.
Oct 2010 Neuronascent receives a Therapeutic Drug Discovery Grant awarded to companies that are presently developing therapeutics for diseases with unmet need. All applicants were examined both by NIH for scientific value and then by the IRS prior to receipt of award. Monies will be spent for further development costs for Neuronascent’s Alzheimer’s and Parkinson’s disease therapeutic candidates.